General information, page-29

I agree that OmniCar / CellPryme/ Car--T therapy is very exciting and down the track when we can afford to reactivate the research intensity with Peter Mac it will be great for Breast Cancer and a number of other diseases, and of course for PTX benefit greatly. But realistically any funds we have available at the moment should be going towards the registration of PTX100, my thoughts are that when the Phase 2A patients results start being reported and of course depending on the response rates that 90% of our funds should be directed towards our PTX100 Phase 2 A outgoings. If we predict that Phase 2A patients respond on par with phase 1 patients and we know that safety is well received by Prof Miles Prince, l can't help but think that after the first 15/20/ or 25 patients instead of 40 responded favorably we would have to be a chance to go straight into a phase 2B study. And then under normal circumstances the process would be preparing for licensing agreements and commerialisation. l would be very surprised if companies didn't have an interest in partnering up with us as we would be commercially very inviting. Hold tight we are getting closer, in the next 6 months or so we should have some feedback on patient results, pharmaceutical shares can be very rewarding but being patient is essential.